History

1991
Pharmalink and Linc are founded

1993
Acquisition of Stille AB

1999
The main project in Calliditas is acquired
Listing of Stille AB

2004
New Pharmalink is formed, projects are separated into their own company (current Calliditas Therapeutics) and sales of product portfolio begin

2005
Pharmalink sells product portfolio to Meda
Sedana Medical is founded

2007
Investment in MedCap

2008
Acquisition of shares in nWise AB

2012
Acquisition of shares in Swevet

2013
Investment in Animal Probiotics

2014
Acquisition of shares in Arcoma

2015
Investment in Athera Biotechnologies

2016
Sale of the holding in Meda
Sale of the holding in Bringwell
Sale of the holding in Boule
Investment in Cinclus

2017
Acquisition of shares in Medivir
Listing of Sedana

2018

Listing of Calliditas in Stockholm
Acquisition of shares in Elos
Investment in Index Pharmacuticals
Investment in Sciety
Investment In Gesynta

2019

Founding of Part Production
Sale of the holding in Midsona

2020

Investment in Epicyt
Investment in Synatro
Investment in Fluoguide
Listing of Callidita’s shares in the USA
Investment in Sixera
Investment in OncoZenge
Investment in AdderaCare
Karl Tobieson is appointed CEO and Thomas Bergh CFO of Linc

2021

Sale of the holding in Elos Medtech
Investment in Initiator Pharma
Investment in OssDsign
Investment in Lantmännen Medical
Listing of OncoZenge
Listing of Linc on Nasdaq Stockholm

2022

Investment in Oncorena
Investment in Egetis Therapeuics
Investment in Melius Pharma
Investment in Alder Therapeutics
Public bid AdderaCare
Divestment of Swevet

2023

Investment in Akiram Therapeutics
Investment in ZalVac
Investment in C-RAD
Investment in Xbrane Biopharma
Divestment of AdderaCare
Divestment of Isofol Medical

2024

Investment in ACE Health
Investment in Oncoinvent
Divestment of Calliditas Therapeutics
Divestment of Xbrane Biopharma